Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2005

Open Access 01-12-2005 | Erratum

Erratum to: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

Authors: Paul D Carey, Bavanisha Vythilingum, Soraya Seedat, Jacqueline E Muller, Michael van Ameringen, Dan J Stein

Published in: BMC Psychiatry | Issue 1/2005

Login to get access

Excerpt

The comment in the introduction of our article [1] suggesting that "quetiapine is the only available antipsychotic with significant 5-HT1D effects," is misleading. The affinity of quetiapine for this receptor is low and probably insignificant when compared with some other second generation antipsychotics [2]. …
Literature
1.
Carey PD, Vythilingum B, Seedat S, Muller JE, van AM, Stein DJ: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry. 2005, 5: 5-10.1186/1471-244X-5-5.CrossRefPubMedPubMedCentral
2.
Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000, 68: 29-39. 10.1016/S0024-3205(00)00911-5.CrossRefPubMed
Metadata
Title
Erratum to: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]
Authors
Paul D Carey
Bavanisha Vythilingum
Soraya Seedat
Jacqueline E Muller
Michael van Ameringen
Dan J Stein
Publication date
01-12-2005
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2005
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-5-44

Other articles of this Issue 1/2005

BMC Psychiatry 1/2005 Go to the issue

Research article

No evidence for association between polymorphisms in GRM3and schizophrenia

Research article

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

Research article

Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features

Research article

Quality of life in patients with personality disorders seen at an ordinary psychiatric outpatient clinic

Research article

The hospital anxiety and depression rating scale: A cross-sectional study of psychometrics and case finding abilities in general practice

Research article

Bright light treatment of depression for older adults [ISRCTN55452501]